DUBLIN, April 08, 2022--(BUSINESS WIRE)--The "Disposable Sterile Insulin Syringe Market Research Report" report has been added to ResearchAndMarkets.com's offering.
The Global Disposable Sterile Insulin Syringe Market size was estimated at USD 349.84 million in 2021 and expected to reach USD 398.12 million in 2022, and is projected to grow at a CAGR 13.97% to reach USD 766.97 million by 2027.
Cumulative Impact of 2022 Russia Ukraine Conflict:
The publisher continuously monitors and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States.
This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.
This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Disposable Sterile Insulin Syringe market considering the current update on the conflict and its global response.
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Disposable Sterile Insulin Syringe Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
The report answers questions such as:
1. What is the market size and forecast of the Global Disposable Sterile Insulin Syringe Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Disposable Sterile Insulin Syringe Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Disposable Sterile Insulin Syringe Market?
4. What is the competitive strategic window for opportunities in the Global Disposable Sterile Insulin Syringe Market?
5. What are the technology trends and regulatory frameworks in the Global Disposable Sterile Insulin Syringe Market?
6. What is the market share of the leading vendors in the Global Disposable Sterile Insulin Syringe Market?
7. What modes and strategic moves are considered suitable for entering the Global Disposable Sterile Insulin Syringe Market?
5.1.1.1. Rising prevalence of diabetic patients worldwide
5.1.1.2. Changing lifestyles and unhealthy dietary habits
5.1.2.1. Rising hospital & clinic spending on safe vaccination
5.1.3.1. Increase in healthcare expenditure and development of self-injection devices & long-acting formulations
5.1.3.2. Innovations and new insulin syringe developments
5.1.4.1. Availability of alternative drug delivery methods
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Disposable Sterile Insulin Syringe Market, by Product
7. Disposable Sterile Insulin Syringe Market, by Application
8. Americas Disposable Sterile Insulin Syringe Market
9. Asia-Pacific Disposable Sterile Insulin Syringe Market
10. Europe, Middle East & Africa Disposable Sterile Insulin Syringe Market
12.3. B. Braun Holding GmbH & Co. KG
12.7. Flextronics International Vita Needle Company
12.12. Hunan Pingan Medical Device Technology Co.,Ltd
12.13. Jiangsu Jichun Medical Devices Co., Ltd.
12.14. Jiangxi Shengsheng Pharmaceutical Co.,Ltd
12.22. Zhejiang Kindly Medical Devices Co., Ltd
For more information about this report visit https://www.researchandmarkets.com/r/aqusjf
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005234/en/
ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
One day after Boeing (NYSE: BA) stock bounced higher on news of a big 737 plane sale to the parent company of British Airways and Iberia (the International Consolidated Airlines Group), shares of the airplane-building juggernaut are falling 7.2% as of 1:10 p.m. ET. The reason: Boeing may be encountering turbulence at higher altitudes. Earlier on Thursday, the big news around Boeing was the company's announcement that International Airlines Group has agreed to buy 25 Boeing 737-8-200 aircraft and 25 737 MAX 10 jetliners -- and taken out an option to buy as many as 100 more planes besides.
Over the past month, the odds of a home price correction spiked. That's according to an analysis CoreLogic ran for Fortune this week.
Shares of the artificial intelligence lender Upstart Holdings (NASDAQ: UPST) traded more than 16% lower as of 11:14 a.m. ET today after it received yet another downgrade from Wall Street. Wedbush analyst David Chiaverini maintained his underperform rating on Upstart but lowered his price target from $20 to $15 per share. The lower price target comes just a week after Chiaverini lowered his price target on Upstart from $35 to $20.
When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett buys or sells shares of a company, Wall Street and investors tend to pay close attention. Since becoming CEO in 1965, he's overseen the creation of more than $680 billion in shareholder value and delivered an average annual return of 20.1% for Berkshire's Class A (BRK.A) shareholders (himself included).
Cathie Wood is a long-time Tesla bull, but the stock isn't the largest holding in Wood's ARK Innovation ETF anymore.
Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna's (NASDAQ: MRNA) shares were down 4.7%.
What happened The ride in Ford (NYSE: F) stock wasn't very smooth on Friday. The big American carmaker saw its shares decline by nearly 3% on a day when the S&P 500 index essentially traded sideways. A ruling from a court overseas was the key catalyst in that deceleration.
Yahoo Finance Live anchors discuss allegations that Elon Musk sexually harassed a flight attendant in 2016.
Yahoo Finance Live anchors discuss second-quarter earnings for Deere.
The markets may be in free fall, but a few biotechnology companies had an exceptionally good day. Siga’s stock is up more than 40%; Emergent Biosolutions’s gained nearly 12%, and Tonix Pharmaceuticals, 15%. A few cases of monkeypox have been registered in Europe and North America, far from West and Central Africa where outbreaks typically emerge.
In this article, we discuss 6 stocks that Warren Buffett is selling in 2022. If you want to see more stocks that the billionaire sold, click Warren Buffett is Selling These 3 Stocks in 2022. Warren Buffett, the chief of Berkshire Hathaway, is perhaps the most renowned financier in the investment world, with decades of […]
In less than week -- Wednesday, May 25 -- Nvidia (NVDA) is due to report its Q1 2022 earnings. Analysts on average are optimistic about the report itself, and also about the guidance Nvidia might give, predicting Nvidia will report 43% growth to $1.30 per share this quarter, and promise investors another 31% worth of growth ($1.36 per share) next quarter. And one analyst thinks Nvidia could do even better than that. Previewing next Wednesday's earnings report, Oppenheimer's Rick Schafer reiterat
High-yield dividend stocks have been viewed more favorably than high-multiple growth stocks these days. After yet another month of excessive market-wide selling, the yields of many top dividend stocks are slightly richer. As the Fed raises interest rates further, growth and value could continue to get slammed. This week, the Fed signaled that it's more than willing to keep the rate hikes coming until inflation backs down, even if it means jeopardizing a "soft landing" and inflicting more pain in
(Bloomberg) -- It’s been hard to watch, impossible to predict and a nightmare to trade. But has the S&P 500’s slide been an unqualified panic to date? By some measures no, and that might bode poorly for equities in the near term. Most Read from BloombergOne of the World’s Frothiest Housing Markets Turned Into a Seller’s Headache OvernightElon Musk Gets Defensive Over Twitter Meme as Harassment Report SurfacesStocks Avert Bear Market, Slide for Seventh Week: Markets WrapApple Shows AR/VR Headset
Shares of Nvidia (NASDAQ: NVDA) continued to tumble on Friday, falling as much as 8%. Wells Fargo analyst Aaron Rakers lowered his price target on Nvidia to $250, down from $370, while maintaining his overweight (buy) rating on the stock, according to The Fly.
Rising interest rates, supply chain constraints and Russia’s invasion of Ukraine are all issues currently plaguing the macro climate. The problem with all three, says Tony Dwyer, Canaccord Chief Market Strategist, is that for each problem there’s “no easy exit strategy.” The tough conditions are likely to persist, then. However, on the plus side, while these issues have sent most corners of the stock market into a tailspin, now investors are presented with stocks for which the term “oversold” re
A bear market for the S&P 500? The stage certainly appears to be set for one, as equity benchmarks added to ugly weekly declines on Friday.
Russia will cut off natural gas to Finland after the Nordic country that applied for NATO membership this week refused President Vladimir Putin's demand to pay in rubles, the Finnish state-owned energy company said Friday, the latest escalation over European energy amid the war in Ukraine.
Harley says it is pausing the all of its production and shipments, except for its electric LiveWire line.
Nio (NYSE: NIO) shares began trading on the main board of the Singapore stock exchange today prior to the opening of the U.S. markets. After initially popping 20% early, the new shares ended up closing in Singapore about 2.4% higher, according to Barron's.